Comparison of the efficacy, safety and patient preference of the phosphodiesterase type 5 inhibitors for the patients with erectile dysfunction

Korean Journal of Urology

Volumn 48, Issue 2, 2007, Pages 219-225

  Yoo, Changhee ^a   Park, Jinsung ^a   Kim, Wansuk ^a   Hong, Bumsik ^a   Hong, Junhyuk ^a   Ahn, Tai Young ^a  

^a University of Ulsan   (South Korea)

Author keywords

Erectile dysfunction; Phosphodiesterase inhibitors; Preference

Indexed keywords

SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG SAFETY; ERECTILE DYSFUNCTION; FLUSHING; GASTROINTESTINAL DISEASE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; OPEN STUDY; PENIS ERECTION; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 34247847897     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.2.219     Document Type: Article

References (27)

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61
2. Sanchez-Cruz J, Cabrera-Leon A, Martin-Morales A, Fernandez A, Burgos R, Rejas J. Male erectile dysfunction and health-related quality of life. Eur Urol 2003;44:245-53
3. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-4
4. Moore RA, Derry S, McQuay HJ. Indirect comparison of interventions using published randomized trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol 2005;5:18
5. The process of care model for evaluation and treatment of erectile dysfunction. The Process of Care Consensus Panel. Int J Impot Res 1999;11:59
6. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-404
7. Omrod D, Easthope SE, Figgitt DP. Vardenafil. Drugs Aging 2002;19:217-27
8. Kuan J, Brook G. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2002;11:1605-13
9. Eardley I, Cartledge J. Tadalafil (Cialis®) for men with erectile dysfunction. Int J Clin Pract 2002;56:300-4
10. Mulhall JP. Understanding erectile dysfunction medication preference studies. Curr Opin Urol 2004;14:367-73
11. Hedelin H, Stroberg P. Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. Drugs 2005;65:2245-51
12. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20mg or sildenafil citrate 50mg during initiation of treatment for erectile dysfunction. Clin Ther 2003;25:2709-23
13. Stroberg P, Murphy A, Costigan T. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003;25:2724-37
14. Mulhall JP, Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol 2006;49:30-7
15. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized controlled trials. Consolidated standards of reporting trials. JAMA 1998;279:1489-91
16. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials explanation and elaboration. Ann Intern Med 2001;134:663-94
17. Porst H, Arnds S, Kleingarn M. The three PDE 5 inhibitors sildenafil, tadalafil, and vardenafil - results of a comparative preference trial in 222 patients with erectile dysfunction. Eur Urol 2004;2(Suppl 3):408
18. Sommer F, Mathers M, Klotz T, Van Ahlen H, Bondarenko B, Ozgur E, et al. Which PDE5 inhibitor do you prefer? A comparative randomized multicenter study of sildenafil, tadalafil, and vardenafil. J Urol 2004;171(Suppl 4):314-5
19. Claes H, Van Poppel H. The use of sildenafil, tadalafil, and vardenafil in clinical practice. J Sex Med 2005;2(Suppl 1):21
20. Park NC, Park HJ, Nam JK, Kim JM. Efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil, and tadalafil: results of an open label study of patient preference in Korea. J Sex Med 2004;l(Suppl 1):55
21. Yoon CJ, Lee SH, Moon KH, Yoo ES, Park JS, Lee KS, et al. The analysis of preference for three PDE-5 inhibitors. Korean J Androl 2005;23:116-21
22. Jackson G, Gillies H, Oterloh I. Past, present, and future: a 7-year update of Viagra® (sildenafil citrate). Int J Clin Pract 2005; 59:680-91
23. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005;96:1323-32
24. Hatzichristou D, Montorsi F, Buvat J, Larerriere N, Bandel TJ, Porst H, et al. The efficacy and safety of flexible-dose vardenafil (Levitra®) in a broad population of European men. Eur Urol 2004;45:634-41
25. Carson CC. PDE5 inhibitors: are there differences? Can J Urol 2006;13(Suppl 1):34-9
26. Montorsi F, Padma-Nathan H, Buvat J, Schwaibold H, Beneke M, Ulbirich E, et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 2004;1:168-78
27. Shabsigh R, Burnett AL, Eardley J, Sharlip ID, Ellsworth PI, Garcia CS, et al. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials. BJU Int 2006;96:857-63